Health Catalyst to Declassify Board, Details Executive Compensation Amid Financial Challenges
HCAT sits 39% above its 52-week low of $0.955.
Summary
Health Catalyst filed its definitive proxy statement, proposing to declassify its board and detailing executive compensation that reflects poor 2025 financial performance, including a large net loss and goodwill impairment.
Key Events · Corporate Governance and Compliance · HCAT
-
Board Declassification Proposed
Shareholders will vote on phasing out the classified board structure, moving to annual director elections by 2029. This is a significant corporate governance change, generally seen as enhancing shareholder rights.
-
Executive Compensation Reflects Poor Performance
Executive performance-based incentives for 2025 were paid out at approximately 15% of target due to significant net losses, goodwill impairment, and missed growth metrics, demonstrating a pay-for-performance alignment.
-
Significant Executive and Board Turnover
The filing details the retirement of the former CEO, resignation of three directors, and departure of two other executive officers, alongside the appointment of a new CEO and a new director, indicating substantial leadership changes.
-
Large Acquisition Details Disclosed
The company completed the acquisition of Upfront Healthcare Services for $41.5 million cash and 5.75 million shares. This represents approximately 7.8% dilution and is a substantial transaction relative to the company's market capitalization, bringing in the current CEO.
Analysis · HCAT · Technology
This definitive proxy statement outlines significant corporate governance changes, including a proposal to phase out the classified board structure, which enhances shareholder rights. It also details executive compensation, revealing that performance-based incentives were significantly underpaid due to the company's substantial net losses and missed growth targets in 2025. The filing provides context on recent executive and board turnover, and a large acquisition that brought in the new CEO, all against a backdrop of severe financial challenges and a recent workforce reduction.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.6% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $1.33 on NASDAQ in the Technology sector, with a market capitalization of approximately $98.3M. The 52-week trading range was $0.96 to $4.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.